Outlook Therapeutics Prices $55M Public Offering with Warrants at $0.99
OTLK has more than doubled off its 52-week low of $0.161 on elevated volume (3.5× avg).
Summary
Outlook Therapeutics priced a $55 million public offering of 55.6 million shares plus warrants at $0.99 per unit, with net proceeds of about $51.1 million to fund the US launch of LYTENAVA.
Updates
· SEC 8-K — Underwriters exercised their option for 8,333,333 additional warrants. GMS Ventures purchased 2,525,252 shares and warrants; CEO Robert Jahr purchased 151,515 and CFO Lawrence Kenyon purchased 101,010.
Key Events · Financing and Capital Events · OTLK
-
Public Offering Priced
55,555,556 shares plus warrants to purchase 55,555,556 shares at combined price of $0.99 per share, for total gross proceeds of $55.0 million.
-
Net Proceeds and Use
Net proceeds of approximately $51.1 million after underwriting discounts and expenses, to fund US commercial launch of LYTENAVA and working capital.
-
Warrant Terms
Warrants exercisable immediately at $1.10 per share, expire five years from issuance; underwriters have 30-day option for 8,333,333 additional shares/warrants.
-
Dilution Impact
Offering increases outstanding shares from 187.1 million to 242.7 million, a 29.7% increase; immediate dilution of $0.75 per share to new investors.
Analysis · OTLK · Life Sciences
Outlook Therapeutics is raising $55 million in a public offering of 55.6 million shares plus warrants, priced at $0.99 per unit. The deal is highly dilutive — the offering nearly doubles the current share count of 187 million — but it provides critical capital to fund the US commercial launch of LYTENAVA, which received FDA approval in July 2026. The company had only $11.2 million in cash as of June 30, 2026, and this raise extends its runway into Q2 2027. The warrants, exercisable at $1.10, add further potential dilution if the stock rises. The offering price is below the last reported sale price of $1.10 on August 12, 2026, indicating a discount to market.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OTLK was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.2M. The 52-week trading range was $0.16 to $3.39. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.